<DOC>
	<DOCNO>NCT01333410</DOCNO>
	<brief_summary>Vitiligo remain difficult disease treat . Previous available therapy often ineffective . It usually take several month year complete repigmentation area body get best partial repigmentation . The desire patient undergo therapy varies patient patient need assess individually . Several factor consider plan treatment strategy include type vitiligo , site degree involvement , skin color , psychological effect , patient compliance , ease ass therapy , cost treatment social association disease . Topical corticosteroid still standard treatment localize vitiligo . However , adverse effect skin atrophy , stria , pigmentary change hypothalamic-pituitary adrenal axis suppression occur use inappropriate strength topical steroid long period time . Tacrolimus ( FK-506 ) new immunosuppressive agent act inhibit T-cell activation cytokine release . It offer safe efficacious alternative many skin condition . It minimize need topical glucocorticoid cause skin atrophy . Tacrolimus first report treatment vitiligo 2002 . The underlie mechanism show vitro study topical tacrolimus promote proliferation melanocytes melanoblast . This study purpose evaluate efficacy safety 0.1 % topical tacrolimus ointment compare 0.1 % mometasone furoate cream treatment adult vitiligo .</brief_summary>
	<brief_title>Comparison Efficacy Safety 0.1 % Tacrolimus 0.1 % Mometasone Furoate Adult Vitiligo</brief_title>
	<detailed_description>At first visit , patient randomize receive 0.1 % tacrolimus ointment apply vitiligo lesion one side body . The lesion side body treat 0.1 % mometasone furoate cream . Patients instruct apply 0.1 % tacrolimus ointment 0.1 % mometasone furoate cream twice day 6 month Patients follow 2 , 4 6 month clinical improvement , side effect photograph</detailed_description>
	<mesh_term>Vitiligo</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>1 . Patients must 18 year old 2 . Patients must symmetrical vitiligo lesion side body . Total vitiligo area exceed 5 % body surface area 3 . Discontinue previous systemic medication phototherapy least 3 month discontinue topical medication least 1 month start study 1 . Patient lesion acral area ( hands foot ) 2 . Pregnancy lactation patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>vitiligo</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>mometasone furoate</keyword>
</DOC>